PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 100 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2024. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $4,000 | -55.6% | 200 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $9,000 | -25.0% | 200 | 0.0% | 0.01% | -25.0% |
| Q2 2018 | $12,000 | -14.3% | 200 | 0.0% | 0.01% | -20.0% |
| Q1 2018 | $14,000 | -30.0% | 200 | 0.0% | 0.01% | -28.6% |
| Q4 2017 | $20,000 | -16.7% | 200 | 0.0% | 0.01% | +40.0% |
| Q3 2017 | $24,000 | +41.2% | 200 | 0.0% | 0.01% | +66.7% |
| Q2 2017 | $17,000 | +142.9% | 200 | 0.0% | 0.01% | +200.0% |
| Q1 2017 | $7,000 | +16.7% | 200 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $6,000 | -53.8% | 200 | 0.0% | 0.00% | -60.0% |
| Q3 2016 | $13,000 | – | 200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 906,642 | $108,570,000 | 5.36% |
| Bain Capital Public Equity Management, LLC | 657,876 | $78,781,000 | 4.97% |
| Perceptive Advisors | 1,847,640 | $221,254,000 | 4.22% |
| Crosspoint Capital Strategies, LLC | 35,788 | $4,286,000 | 3.32% |
| ASCEND CAPITAL, LLC | 716,717 | $85,828,000 | 3.24% |
| PFM Health Sciences, LP | 1,369,579 | $164,007,000 | 3.22% |
| Orbimed Advisors | 2,425,735 | $290,482,000 | 2.78% |
| Boxer Capital, LLC | 100,000 | $11,975,000 | 2.73% |
| Partner Investment Management, L.P. | 21,294 | $2,550,000 | 2.42% |
| FT Options LLC | 11,438 | $1,370,000 | 2.06% |